Introduction
The central nervous system (CNS) offers a unique target for viral gene transfer. Expression of therapeutic proteins may be useful in treating several CNS disorders. Moreover, the blood-brain barrier partially protects the brain from extensive immune response. Although gene transfer to the CNS of mammals has been accomplished with several vectors, each system has limitations. [1] [2] [3] [4] [5] [6] Such approaches to treat primary and secondary CNS diseases, including neuro-AIDS, have so far yielded very limited results. [7] [8] [9] [10] [11] [12] [13] [14] Efficient gene transfer and stable gene expression are two key features required for effective gene therapy for many congenital and acquired disorders. Recombinant T-antigen (Tag)-deleted SV40-derived viral vectors (rSV40s) infect a wide range of cell types from humans and other mammals. Although levels of protein production tend to be lower than are seen with other vector systems, rSV40s deliver genes to nondividing cells efficiently and achieve long-term transgene expression in vitro and in vivo. [15] [16] [17] rSV40 vectors are able to transduce 495% of cultured human NT2 precursor cells as well as NT2-derived neurons 18, 19 and microglia 20 without detectable toxicity and selection.
The goal of the present study was to determine the most effective routes of administration of SV40 vectors to the brain and the parameters of transduction. Distribution of transgene expression in the brain is an important parameter to consider, as well as the number and type of transduced cells. A better understanding of these parameters would allow us to coordinate administration of rSV40s with therapeutic or investigative goals, so as to optimize transduction. Here, vectors were administered stereotaxically into the lateral ventricle (LV) or caudateputamen (CP) of rats. Transgene expression was assessed by immunohistochemistry and Western blotting. We used both a marker transgene with a FLAG epitope and a transgene of potential therapeutic interest (Cu/Zn superoxide dismutase, SOD1) to achieve long-term transduction of neurons and microglia. Intraventricular vector administration provided widespread transduction, particularly when mannitol was given systemically in conjunction.
Results

Transgene expression after intraparenchymal rSV40 injection
The distribution of FLAG transgene expression was studied by immunocytochemistry on cryostat sections of rat brains whose CP has been injected stereotaxically with SV(Nef-FLAG). Numerous transgene-positive cells were observed a week after injection of SV(Nef-FLAG) into the CP; no cells on the uninjected contralateral side were immunopositive for FLAG. No expression of FLAG was observed after injection of saline or SV(BUGT) instead of SV(Nef-FLAG). Control sections incubated with nonimmune primary antibody were negative ( Figure 1a ). FLAG-positive cells were seen at all time points (Figure 1b) , the latest assay point being 84 days postinjection.
The distribution of transgene-expressing cells was examined on serial coronal cryostat sections. As an example, 7 days after injection, transgene-positive cells were seen on sections at least 4 mm apart longitudinally, and not only in the CP, but also, much less frequently, in different brain structures along the needle track (NT) (Figure 1c) . The longitudinal extent of the transduced area was similar along the whole CP for all time points after 4 days (Figure 1d ). Transgene-expressing cells were enumerated every tenth section as a means to provide comparisons of vector distribution, dose effects and durability of transduction. The numbers are not absolute counts of total transduced cells in the brain, but rather of those immunopositive cells seen in the 10 mm thick sections examined, taken 0.1 mm apart. More transgenepositive cells were observed when 10 ml of vector was given than with an injection of 1 ml. One month after the injection of 10 ml SV(Nef-FLAG) in the CP, the estimated number of FLAG-positive cells in the whole striatum was around 400 000. (Figure 1e : note that the scale is logarithmic).
Characterization of transduced cells after injection of SV(Nef-FLAG) into the CP
To determine which cell types were transduced by SV(Nef-FLAG), we used immunocytochemistry to stain representative sections of brains harvested at different time points (4-84 days) after injection of the vector into the CP. Sections were double-stained for FLAG and either NeuN, MAP2 or tyrosine hydroxylase (TH) (neuronal markers), glial fibrillary acidic protein (GFAP, astrocyte marker) and CD68, C3bi and CD11b (microglial cell markers). In the CP, more than 95% of transgeneexpressing cells stained positively for NeuN or MAP2, indicating substantial neuronal transduction ( Figure 2 ). No expression of FLAG was observed in controls injected with SV(BUGT) or saline (not shown). There was no immunostaining for FLAG on the uninjected side ( Figure  2a ). Immunostaining controls omitting the primary antibody were also negative (not shown). Some dopaminergic neurons (immunostained with antibody against TH) were transduced with the vector (not shown). Numerous neurons were transduced in the vicinity of the NT (not shown). Astrocytes generally did not express the transgene (Figure 3a and b ). An increased number of astrocytes, however, was observed on the edges of the NT by day 14 probably reflecting reparative gliosis following the needle-related lesion (Figure 3c ). Few microglial cells (recognized by antibodies against CD68 and CD11b-C3bi) expressed FLAG ( Figure 4) . No transgene-expressing oligodendrocytes were observed.
Absence of retrograde transport of SV(Nef-FLAG) or the Nef-FLAG protein Because retrograde transport offers a potential means of vector delivery to specific areas that are not directly injected, or that may be inaccessible to direct injection, we tested FLAG expression in the substantia nigra (SN), a region that provides dopaminergic afferents to the caudate area. There was no detectable expression of FLAG in the SN, whereas the neurons expressed TH. Thus, retrograde transport of SV(Nef-FLAG) or the Nef-FLAG protein from the CP to the SN probably does not occur with rSV40 gene delivery to CNS cells ( Figure 5 ).
rSV40 gene transfer to the brain does not elicit inflammatory responses
On the sections stained by neutral red (NR), no inflammation was seen in brains given SV(Nef-FLAG) either in the CP or LV 4-14 days postinjection (not shown). Likewise, no CD8-positive T cells were identified (not shown). Finally, no inflammation was seen in the brain 1, 2 or 3 months after injection of SV(Nef-FLAG), saline or SV(BUGT) (not shown).
Expression of SOD1 after injection of SV(SOD1) in the CP
As an example of therapeutically applicable gene transfer to the brain, we studied rSV40-mediated delivery of SOD1. SV(SOD1) was injected into the CP on one side of the brain, but not the other. SOD1 expression was assessed 1, 2 and 4 weeks thereafter. One month after injection, numerous cells were expressing the transgene, most of them stained by NT, a neuronal marker (Figure 6a ). There was no expression of FLAG on the sections of the brains injected with SV(SOD1), nor for SOD1 in brains injected with SV(Nef-FLAG) (Figure 6a 
Intraventricular injection of rSV40s leads to widespread transgene expression
To determine whether rSV40 gene delivery could provide more extensive transduction, we tested vector administration into LV. SV(SOD1), or control SV(BUGT), was injected into the LV of rats at five times the dose used for intraparenchymal injection. Immediately after the procedure, the injected side was kept lower than the contralateral side for 15 min, after which the animals were righted. One month later, tissue was examined by immunostaining, and Western blotting immunohistochemistry showed that SOD1 expression was greatest in the ependyma and choroid plexus lining the ventricle (not shown). However, Western blot analysis of cortical brain demonstrated strong SOD1 expression, particularly marked in the cortex from the side of the intraventricular administration ( Figure 7a ). Increased expression was also seen in frontal cortex from the opposite side. rSV40-mediated gene delivery to the brain in vivo J-P Louboutin et al
Improving the effectiveness of LV injection using mannitol
We then asked whether gene delivery LV injection of rSV40s might be facilitated by intraperitoneal (i.p.) mannitol 30 min before LV injection of SV(SOD1). This procedure increased the numbers of neurons that were immunopositive for SOD1 (not shown) and led to far greater expression of SOD1 in the frontal cortex as demonstrated by Western blot analysis ( Figure 7b ). Frontal cortex from rats receiving SV(BUGT) control vector did not produce SOD1 detectably.
Discussion
Gene transfer into the brain has been achieved using various viral vectors. Adenoviral-mediated gene transfer to the brain may achieve a high degree of gene expression, but is limited by several factors. 1, 2 There are innate and acquired immune responses not only against the virus, but to foreign transgenes as well, which limit the duration of transient gene expression. 21 The development of gutted vectors, manipulation of host immune responses and use of less immunogenic transgenes have been proposed to circumvent these limitations, but success to date has been limited. 22, 23 Vectors derived from adeno-associated viruses (AAV) elicit little, if any, damage or inflammatory response after intracerebral injection, and may deliver long-term transgene expression to nondividing cells in multiple tissues, including the brain. 24 However, the size of the transgene inserted must be smaller than 4 kb. Tropism and transduction efficiencies of AAVs can be modified by using different AAV serotypes. [25] [26] [27] Widespread distribution of the transgene can be achieved using AAVs. 28, 29 Vectors derived from oncoretroviruses (such as MuLV) integrate into the genome of target cells without transferring expression of any native viral genes, properties considered crucial for sustained transgene expression. These vectors, however, only transduce cells that rSV40-mediated gene delivery to the brain in vivo J-P Louboutin et al divide shortly after infection. 30 Lentiviral vectors can transduce some postmitotic cells, including neurons. Gene transfer to the rodent and primate CNS in vivo has been demonstrated with lentiviral vectors derived from HIV and other lentiviruses, delivering both marker and potentially therapeutic genes. 5, 6, 31 We used rSV40 vectors here to deliver both a marker gene and a potentially useful therapeutic gene into the brain. rSV40s were employed in the current study because they transduce cells in G0 with high efficiency and integrate into their genomes to provide permanent transgene expression. We observed efficient, sustained gene transfer to rat brain: injection in the CP resulted in numerous cells expressing the transgene. Transgene expression continued undiminished for the 3-month duration of these studies, which time is commonly presented as reflecting long-term expression of transferred genes. This is consistent with other studies in which rSV40 transduction of several organs has proven long lived. [32] [33] [34] [35] The present study demonstrates that a single injection of SV40-derived vectors into the brain can transduce brain cells. Unlike adenoviruses, rSV40s do not elicit inflammatory responses. They can also carry somewhat larger transgenes (5 kb) than does AAV. Besides the type of virus, the absence of any inflammatory response may also reflect the nature and level of transgene expression. Interestingly, the estimated number of cells that expressed the rSV40-delivered transgene (between 400 000 and 500 000) is similar to the figures obtained using AAV2/5, perhaps the best rAAV for transducing the striatum. 27 Moreover, the number of transgene-positive cells was stable throughout the 3-month study period after injection, whereas transgene expression reportedly declines over time with rAAV 7 and adenovirus vectors. In the present study, we found rSV40 vectors to be effective at transducing both neurons and microglia, on intracerebral inoculation. Transduction of cultured NT2-derived neurons by rSV40 vectors has been reported previously, 18, 19 and effective rSV40-mediated gene transfer to microglia has been shown as well in culture. 36 rSV40 vectors did not transduce astrocytes appreciably in these studies in vivo; astrocytes similar results have been obtained using cultured atrocytes (L Agrawal et al., unpublished). In contrast, these vectors delivered genes very effectively to microglia, which have rarely been reported as targets for gene therapy. Preliminary studies also found evidence of gene transfer by intracerebral injection of SV-based vectors targeting the basal ganglia. 37 We recently reported that injection into the rat CP of HIV-1 envelope gp120 can induce neuronal apoptosis, and that in vivo transduction with SV(SOD1) substantially protected neurons from that apoptosis. 38 These findings further support the possibility that these vectors may be useful for CNS-directed gene delivery in vivo.
In vivo transduction of neurons by rSV40 vectors was illustrated using intraventricular administration in a preliminary study, but applying substantially higher doses than were used here. 19 In the present study, we demonstrate a sustained transgene expression after injection of rSV40 vectors in the LV. Moreover, systemic mannitol-induced hyperosmolarity improves transgene expression after injection of SV(SOD1) in the LV, most likely by increasing the number of cells exposed to the administered vector. Few studies have been reported concerning the effects of a prior injection of mannitol on transgene expression in the brain, some were based on the injection of AAVs into the striatum 39 or the cisterna magna 28 or adenovirus administration into the LV. 40 It may be possible to increase percentages of transgene-positive cells further using multiple inoculations. This approach increases numbers of rSV40-transduced cells in studies in vivo targeting other organs. [32] [33] [34] [35] In this respect, rSV40 vectors have a unique advantage: rSV40-mediated gene delivery to the brain in vivo J-P Louboutin et al repeated studies have shown that they do not elicit detectable neutralizing immune responses, and that consecutive administrations may be given in rapid sequence or with lengthy time intervals in between. Thus, multiple dosing is possible without loss of gene delivery efficiency. 41 The transparency of the virus to the immune system, which accounts for this unique capability, probably reflects the virus' unusual route of entry, which avoids antigen processing even in transduction of professional antigen-presenting cells. 42, 43 Whatever the mechanism, the absence of detectable neutralizing antibodies allows for multiple administrations of rSV40s without loss of gene transfer efficacy because of vectorspecific immune responses. [44] [45] [46] One of the markers transgene used, the FLAG epitope, was appended to a carrier protein, in this case, HIV-1 Nef. This approach, using an antibody-recognized intracellular antigen, differs from techniques used in other studies. 'Traditional' marker genes, such as the fluorescent proteins, or b-galactosidase, are not expressed well when delivered by rSV40 vectors. The reasons for this are not entirely clear, but the COS-7 cells that package these vectors appear to recognize and inactivate invertebrate or prokaryote DNAs (Strayer et al., in preparation). Other mammalian DNAs, and genes from mammalian viruses, are largely expressed effectively by these vectors. Nonetheless, levels of protein expression, though durable and not prone to posttransduction silencing, tend to be lower than are seen with, for example, adenoviral vectors -perhaps for the same reasons.
We did not detect transgene expression in the SN after injection of SV(Nef-FLAG) in the CP, suggesting that these vectors are not transported retrograde across synapses. No evidence of retrograde transport or diffusion from the striatum to the SN was shown for Mokola and VSV-G vectors carrying b-gal in the study of Watson et al., 8 whereas low-level retrograde transport of a VSV-G-pseudotyped HIV vector was reported in the nigrostriatal pathway. 31 Transport of viruses along the length of cellular extensions, however, has been described for VSV-G-and Mokola-pseudotyped HIV vectors 47, 48 and for FIV and AAV2/5. 49 Retrograde axonal transport is an important mechanism for transducing neurons in rSV40-mediated-gene transfer to the brain may, thus, be approached from the perspective of local intraparenchymal injection or intraventricular administration to achieve more widespread transgene expression. Further increases in transduction may be approachable using higher doses, repeated dosing and other agents such as mannitol to increase cellular accessibility to the vector. Less invasive routes of administration, for example intravenously (i.v.), again perhaps in combination with manipulation to increase the permeability of the bloodbrain barrier may also be useful. 28 There is some evidence that systemically administered rSV40 vectors can cross the blood-brain barrier, albeit in small quantities (JR Chowdhury et al., preliminary studies). 33 We have demonstrated that rSV40s are effective gene delivery vehicles for either localized or widespread use in the CNS. Their lack of antigenicity and ability to transduce nondividing cells make rSV40 vectors attractive vehicles for CNS gene transfer in settings, where efficient and sustained gene transfer is desired.
Materials and methods
Animals
Female Sprague-Dawley rats (200-250 g) were purchased from Charles River Laboratories (Wilmington, MA, USA). Protocols for injecting and euthanizing animals were approved by the Thomas Jefferson University IACUC, and are consistent with AAALAC standards.
Antibodies
Different primary antibodies were used: mouse and rabbit anti-FLAG (1:100), rabbit anti-GFAP antibodies (1:100) (Sigma, St Louis, MO, USA), rabbit anti-GFAP (1:200) (Immunostar, Inc., Hudson, WI, USA), mouse anti-NeuN (1:100) (Chemicon International, Temecula, CA, USA), mouse anti-rat CD68/ED1 (1:50) (Serotec, Oxford, UK), mouse anti-OX-42 (rat CD11b) (1:50) (Accurate Chemical and Scientific Corporation, Westbury, NY, USA), rabbit anti-human SOD1 (1:100) (Stressgen, Victoria, BC, Canada). Secondary antibodies were used at 1:100 dilution: FITC and Tetramethyl Rhodamine Iso-Thiocyanate (TRITC)-conjugated goat anti-mouse, TRITC-conjugated goat anti-rabbit, FITC-conjugated sheep anti-rabbit (Sigma), fluorescein isothiocyanate and TRITC-conjugated donkey anti-mouse antibodies (Jackson ImmunoResearch Laboratories, Inc., WestGrove, PA, USA).
Vector production
The general principles for making recombinant replication-defective SV40 viral vectors have been reported previously. 51 Briefly, the cloned rSV40 genome was excised from its carrier plasmid, gel-purified and recircularized, then transfected into COS-7 cells. These cells supply in trans large Tag and SV40 capsid proteins, which are needed to produce recombinant replicationdefective SV40 viral vectors. 17 Crude virus stocks were prepared as cell lysates, then band-purified by discontinuous sucrose density gradient ultracentrifugation and titered by Q-PCR. 52 The cDNA for HIV Nef with a Cterminal FLAG epitope tag was driven by a CMV-IEP promoter. For humans, SOD1 was driven by the Rous Sarcoma Virus long-terminal repeat (RSV-LTR). SV(BUGT), which was used here as negative control vector, has been reported. 35 
Experimental design
For SV(Nef-FLAG) studies, different time points (4, 7, 14, 28, 56, 84 days) were assayed after SV(Nef-FLAG) injection into the CP, two rats at each time point. In addition, 50 ml of SV(Nef-FLAG) was injected into the LV of four rats, whose brains were examined 28 days (n ¼ 2) and 56 days (n ¼ 2) after the injection. SV(SOD1) was injected into the CP of 16 rats, whose brains were harvested 1, 2, 4 and 8 weeks after injection, four rats at each time point. 50 ml of SV(SOD1) was injected into the LV of eight rats, whose brains were examined 28 (n ¼ 4) and 56 days (n ¼ 4) after injection.
For the mannitol study, 3 ml of sterile 25% mannitol in 0.9% saline/100 g body weight was injected intraperitoneally 20 min before injection of 50 ml of SV(SOD1) into the LV in eight rats. Their brains were examined 4 and 8 weeks after the injection of the vector (n ¼ 4 for each time points). In all cases, controls received saline or SV(BUGT) rSV40-mediated gene delivery to the brain in vivo J-P Louboutin et al instead of SV(Nef-FLAG) and SV(SOD1) in the CP and the LV.
In vivo transduction
Rats were anesthetized with isofluorane UPS (BaxterHealthcare Corp., Deerfield, IL, USA) (1.0 unit isofluorane/1.5 l O 2 /min) and placed in a stereotaxic apparatus (Stoelting Corp., Wood Dale, IL, USA) for cranial surgery. Body temperature was maintained at 371C by using a feedback-controlled heater (Harvard Apparatus, Boston, MA, USA). Glass micropipettes (1.2 mm outer diameter; World Precisions Instruments, Inc., Sarasota, FL, USA) with tip diameters of 15 mm were backfilled with 1 or 10 ml of rSV40(Nef-FLAG) viral vector. One micro liter of rSV40(Nef-FLAG) viral vector stock contains approximately 2.5 Â 10 8 infectious virus. The vector-filled micropipettes were placed into the LV or CP using coordinates obtained from the rat brain atlas of Paxinos and Watson. 53 For injection into the CP, the burr hole was placed +0.48 mm anterior to the bregma and À3.0 mm lateral to the sagittal suture. Once centered, the micropipette was placed 6.0 mm ventral from the top of the brain. For LV injection, the burr hole was placed À0.26 mm posterior to bregma and À1.0 mm lateral to the sagittal suture. Once centered, the micropipette was placed À3.4 mm ventral from the top of the brain. The vector was administered by a Picospritzer II (General Valve Corp., Fairfield, NJ, USA) pulse of compressed N2 duration 10 ms at 20 psi until the fluid was completely ejected from the pipette. Following surgery, animals were housed individually with free access to water and food.
After a variable survival period, rats were anesthetized via i.p. injection of sodium pentobarbital (Abbott Laboratories, North Chicago, IL, USA) at 60 mg/kg and perfused transcardially through the ascending aorta with 10 ml heparinized saline followed by ice-cold 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA, USA) in 0.1 M phosphate buffer (pH 7.4). Immediately following perfusion-fixation, the rat brains were dissected out, placed in 4% paraformaldehyde for 24 h, then in a 30% sucrose solution for 24 h, 
Immunocytochemistry
For immunofluorescence, coronal cryostat sections (10 mm thick) were processed for indirect immunofluorescence. Blocking was carried out by incubating 60 min with 10% goat, or 10% donkey, serum in phosphate buffer saline (PBS; pH 7.4). Then, sections were incubated with antibodies diluted according to the manufacturer's recommendations: 1 h with primary antibody, then 1 h with secondary antibody diluted 1/100, all at room temperature. Double immunofluorescence was carried out as described previously. 54 All incubations were followed by extensive washing with PBS. To stain nuclei, we used mounting medium containing 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA). Specimens were finally examined under a Leica DMRBE microscope (Leica Microsystems, Wetzlar, Germany). Negative controls consisted of preincubation with PBS and 0.1% bovine serum albumin (BSA), substitution of nonimmune isotypematched control antibody for primary antibody, and/or omission of the primary antibody.
Staining of neurons using NeuroTrace
After rehydration in 0.1 M PBS, pH 7.2, sections were treated with PBS plus 0.1% Triton X-100 for 10 min, washed twice for 5 min in PBS and then stained by NeuroTrace (Molecular Probes, Inc., Eugene, OR, USA) (1:100), a fluorescent Nissl stain, for 20 min at room temperature. Sections were washed in PBS plus 0.1% Triton X-100, washed twice with PBS and let stand for 2 h at room temperature in PBS before being counterstained with DAPI. Combination NT+ antibody staining was carried out using primary and secondary antibodies staining first (see above) followed by staining with the NT fluorescent Nissl stain. Experiments were repeated three times and carried out on the same day for the different sections considered.
General morphology
Microscopic morphology of the brain was assessed by NR staining of cryostat sections.
Morphometry
Transduction was assessed for each injected brain (LV and CP injections) by serial cryosectioning of the whole brain (10 mm thick coronal sections), each slide being numbered, then by immunostaining of every fifth section for FLAG or SOD1 (i.e., at 50 mm intervals, spanning at least 3 mm of tissue rostral and 3 mm caudal to the injection site). This step determined the most anterior and posterior extent of the transduced area. Between 100 and 120 sections were immunostained for each rat. The total number (and not the number in random areas) of FLAG-or SOD1-positive cells in one hemisphere for every fifth section was counted and summed. The final number presented was an average of the results measured in the different sections examined. The total number of positive cells in a brain could be estimated by 'multiplying' the cell counts by the length of the transduced area, assuming that the number of positive cells in the sections spanned between first and fifth one, for example, will be close to the one measured on these first and fifth sections. This procedure, already described for assessment of numbers of transgenepositive cells in the brain, 7, 25 allows quantitative and relative comparisons among different time points, although it does not reflect the total number of transduced cells in vivo. However, if these calculations of cell counts do not conform to unbiased stereological method, they are realized on 10 mm thick sections and the total number of positive cells is counted in each section, whereas stereological methods are usually applied to 40-50 mm thick sections and analyze random fields of the sections. Moreover, we used our current method for evaluating total numbers of neurons in the rat normal striatum using immunocytochemistry (using antiNeuN antibodies) and staining of neurons by Neurotrace. Preliminary results showed a total number of neurons close to the one measured using the optical fractionator method (not shown).
The longitudinal distribution of the transgene away from the injection site was assessed, as the distance comprised between the most distant sections anterior and posterior to the injection site demonstrating transgene expression. 
Western blot analysis
For in vivo protein analysis, brain sections were homogenized in buffer containing protease inhibitors and DNase. Lysates were prepared as reported previously. 38 Total protein was estimated using BCA protein assay kit (Pierce, Rockford, IL, USA). Total cell proteins (100 mg) were loaded in each well, then transferred to Immobilon-P Poly Vinylidine difluoride membrane (Millipore Inc., Billerica, MA, USA). Equal lane loading was assessed by using anti-glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) antibody (1:5000). The blot was realized according to the manufacturer's instructions (Roche, Indianapolis, IN, USA). Anti-SOD1 antibody was used at dilutions of 1:500, and anti-rabbit Horseradish peroxidase was used at a dilution of 1:5000 before the addition of chemiluminescence substrate (Roche).
